Purpose: We present a systematic screening for identifying associations between prescribed drugs and cancer risk using the high quality Danish nationwide health registries. Methods: We identified all patients (cases) with incident cancer in Denmark during 2000-2012 (n = 278,485) and matched each case to 10 controls. Complete prescription histories since 1995 were extracted. Applying a two-phased case-control approach, we first identified drug classes or single drugs associated with an increased or decreased risk of 99 different cancer types, and further evaluated potential associations by examining specificity and dose-response patterns. Findings: 22,125 drug-cancer pairs underwent evaluation in the first phase. Of 4561 initial signals (i.e., drug-cancer associations), 3541 (78%) failed to meet requirements for dose-response patterns and specificity, leaving 1020 eligible signals. Of these, 510 signals involved the use of single drugs, and 33% (166 signals) and 67% (344 signals) suggested a reduced or an increased cancer risk, respectively. While a large proportion of the signals were attributable to the underlying conditions being treated, our algorithm successfully identified well-established associations, as well as several new signals that deserve further investigation. Conclusion: Our results provide the basis for future targeted studies of single associations to capture novel carcinogenic or chemopreventive effects of prescription drugs.
Introduction
Identification of unintended effects of drug therapy is an essential part of post-marketing drug surveillance (pharmacovigilance), as knowledge of rare side-effects is limited at the time of marketing of new medications (Strom et al., 2012) . Unintended effects of drugs may involve an increase or a reduction in cancer risk (International Agency for Research on Cancer, 2012; Umar et al., 2012) . Although systematic and comprehensive testing of genotoxicity and carcinogenicity is performed for any new drug prior to marketing (Brambilla and Martelli, 2009) , both these laboratory assays and the premarketing phase-3 trials are disadvantaged by the typically long latency period of cancer development in humans (Umar et al., 2012; Burstein and Schwartz, 2008) . For example, the excess risk of breast cancer induced by use of menopausal or contraceptive hormone therapy first becomes apparent after 5-10 years of continued use (Howell and Evans, 2011; Zhu et al., 2012) , and the protective effect of aspirin against colorectal cancer requires at least five years of regular use Cuzick et al., 2015) . Traditional approaches in pharmacovigilance (based primarily on spontaneous reporting of adverse events) rarely detect drug-cancer associations, primarily due to the long induction time of most cancer types, which separate the use of the drug from the diagnosis by several years. As most individual cancer types are rare and have a long latency, pre-marketing clinical trials are unlikely to detect carcinogenic or chemopreventive effects of drugs due to the typically small size and short follow-up of these trials. Since neither spontaneous reporting nor clinical trials would be effective in capturing signals, the primary tool in surveillance of drugs for unintended carcinogenic or cancer preventive effects would be analyses of large administrative databases. Such studies have been instrumental in the identification of carcinogenic effects of several drugs, e.g., female hormone therapy and phenacetin (International Agency for Research on Cancer, 2012) .
Denmark has a long history of establishing nationwide health care registries and databases with information on all Danish residents (Thygesen and Ersbøll, 2014) . Two of the nationwide registries with the highest data quality, the Danish Prescription Registry (initiated in 1995 (Kildemoes et al., 2011) ) and the Danish Cancer Registry (established in 1943 (Gjerstorff, 2011) ), hold virtually complete data on drug prescriptions and incident cancer cases and thus provide a unique setting for active surveillance of cancer risk associated with the use of prescription drugs.
We established a system to screen for associations between prescription drug use and cancer risk, based on a multiple case-control design. In the present paper, we describe (i) the source population and data sources, (ii) the initial screening process, (iii) the strategy for internal validation of signals, and (iv) initial results from the nationwide screening.
Setting and Data Sources

Data Sources
The entire Danish population is provided free tax-supported medical care by the National Health Service (Thygesen and Ersbøll, 2014) . For administration and maintenance of this health care system, numerous administrative and health registries have been established. In addition to supporting high quality service in the health care system, these registries allow population-based studies covering all residents in Denmark (approximately 5.6 millions).
The main data sources for our screening system include the Danish Cancer Registry (Gjerstorff, 2011) , the Danish Prescription Registry (Kildemoes et al., 2011) , the Danish National Patient Registry (Lynge et al., 2011) , and the Danish Civil Registration System (Pedersen, 2011) .
The Danish Cancer Registry (Gjerstorff, 2011) has recorded incident cancer cases on a nationwide basis since 1943 and has been shown to have accurate and almost complete ascertainment of cases (Gjerstorff, 2011; Statens Serum Institute and Danish Cancer Society, n.d.) . Approximately 90% of cancer cases in the registry are histologically verified, while the remaining are mainly represented by brain tumours and cancers in very old and/or frail patients. Cancer diagnoses are recorded using the International Classification of Diseases, version 10 (ICD-10), and the ICD for Oncology (ICD-O-3).
The Danish National Prescription Registry (Kildemoes et al., 2011) contains data on all prescription drugs dispensed to Danish residents since 1995. The data include the type of drug, date of dispensing, and quantity dispensed. Drugs are categorized according to the Anatomical Therapeutic Chemical (ATC) index, a hierarchical classification system developed by the WHO (WHO Collaborating Centre for Drug Statistics Methodology, 2014).
The Danish National Patient Register (Lynge et al., 2011) contains nationwide data on all non-psychiatric hospital admissions since 1977 and all outpatient specialist contacts in hospital setting since 1995. Discharge/contact diagnoses are coded using ICD-8 (1977 ICD-8 ( -1993 and ICD-10 (1994-) .
The Danish Civil Registration System (Pedersen, 2011) contains data on vital status (date of death) and migration to and from Denmark, allowing sampling of general population controls and complete tracking of study subjects.
Data Linkages
Data sources were linked by the civil registry number, a unique identifier assigned to all Danish residents since 1968 (Pedersen, 2011) . Linkage was performed within Statistics Denmark, a governmental institution that collects and maintains electronic records for a broad spectrum of statistical and scientific purposes (Thygesen et al., 2011a) .
Identification of Cancer Cases
From the Danish Cancer Registry, we identified all individuals in Denmark with incident cancers diagnosed between January 1, 2000 and December 31, 2012. We defined the index date as the date of diagnosis. Cases were restricted to histologically verified cancers (except for tumours of the central nervous system, of which some are based on clinical and imaging findings only, and haematological malignancies).
Exclusion criteria were age outside 18-85 years at index date and migration to or from Denmark anytime during the 10 years prior to index date. This ensured at least 10 years of complete follow-up prior to sampling for all study subjects and a minimum of five years of prescription data (available from 1995). We excluded the youngest since both drug use and cancer incidence are low among children and adolescents. We further excluded individuals with a previous history of cancer (except non-melanoma skin cancer) thus focusing on primary incident cancers.
Based on ICD-O topography and morphology codes for 34 cancer sites, we restricted the cancer outcomes to 99 cancer subtypes. For a complete list of the included cancers and their definitions within the Cancer Registry, see Appendix A.
Selection of Controls
Controls were selected using risk set sampling. For each case, we randomly selected 10 controls from all Danish citizens applying the same exclusion criteria as for cases and with the same sex and birth year as the case. Controls were assigned an index date identical to that of the corresponding case. Each subject was eligible for sampling as a control before becoming a case and could be sampled as a control more than once. Thereby, the calculated odds ratios (ORs) provide unbiased estimates of the corresponding incidence rate ratios (IRRs) that would have emerged from cohort studies conducted in the underlying source population (Rothman et al., 2008) .
Approvals and Funding
The study was approved by the Danish Data Protection Agency. According to Danish law, studies based solely on register data do not require approval from an ethics review board (Thygesen et al., 2011a) . The study was funded by the Danish Council for Independent Research (grant 4004-00234B). The funder had no role in the study conduct, interpretation of data, or reporting of the findings.
Initial Screening Process
The process consisted of two stages. In the first stage, we identified potential signals, i.e., drug-cancer associations. Those associations meeting our strength criteria qualified for further evaluation of causation in the second stage (see "Evaluation of Signals" below).
Classification of Drug Exposures
For each cancer or cancer subtype in the screening process, we included all drugs and drug classes that either had 10 observed longterm users (defined as ≥8 prescriptions) among the cases or where 10 cases were expected to be long-term users based on drug exposure among the controls given no drug-cancer association. Single drugs were defined by the fifth level of the ATC-system (e.g., C07AB02, metoprolol), and drug classes were analysed at both the second (e.g., C07, all beta-blockers) and fourth level (e.g., C07AB, selective beta-blockers).
Exposure to a specific drug or drug class was assessed from prescription fills recorded in the Prescription Registry prior to the index date for cases and controls. We classified use as non-use (0-1 prescription), intermediate use (2-7 prescriptions), and long-term use (≥ 8 prescriptions). Eight prescriptions was chosen as a cut-off as drugs for chronic treatment are typically supplied for 3 months use for each dispensing in Denmark, whereby our definition of long-term use would correspond to two years' cumulative treatment.
In all assessments of primary drug exposures or confounders, we disregarded prescriptions redeemed within one year prior to the index date. This was done for two reasons. First, such recent exposure is unlikely to be associated with cancer development (International Agency for Research on Cancer, 2012; Umar et al., 2012) . Secondly, drug use has been shown to increase in the year prior to cancer diagnoses (Jørgensen et al., 2012) , likely due to treatment of early symptoms of yet undiagnosed cancers. Such treatment patterns raise the possibility of reverse causation bias (Csizmadl et al., 2007) .
First-level Screening
The analyses followed a conventional matched case-control approach using conditional logistic regression. We estimated odds ratios (OR) for each individual cancer outcome associated with the drug exposures by comparing long-term use (≥8 fills) to non-use (i.e., disregarding intermediate use). Potential confounding by gender, age, and calendar time was handled by the design (matching) and conditional analysis. We further adjusted for Charlson Comorbidity Index (CCI) score (Charlson et al., 1987; Thygesen et al., 2011b ) (categorized as 0, 1, 2, 3 or 4+) using information on medical history recorded in the Patient Registry from 1977 up to one year prior to index date, and years of schooling (categorized into basic [≤10 years], short/medium [11-13 years], long [14+ years], or missing) (Dalton et al., 2008) .
All analyses were performed using Stata Release 13.0 (StataCorp, College Station, TX, USA).
Definition of Signals
Following the initial analysis, we identified all drug-cancer pairs meeting our criteria for strength of association. Signals were defined as drug-cancer associations with an OR greater than 1.5 or less than 0.67, or a lower limit of the 95% confidence interval above 1.2 or a higher limit below 0.83.
Evaluation of Signals
All signals identified in the initial screening procedure were examined further according to two additional criteria: (i) specificity and (ii) dose-response relationship.
Outcome Specificity
Signals were tested for specificity, i.e., whether the drug was associated with a particular cancer types or with cancer overall. No drug is known to increase the risk of all cancer types, and absence of specificity of the signals thus suggests the existence of bias, e.g., residual confounding by smoking or other factors such as surveillance. In the test for specificity of a given signal, we compared the point estimate for any drugcancer association with the particular drug's association with cancer overall. To meet the criteria for specificity, we required that the ratio of the OR for the signal to the overall OR was outside the range of 0.83-1.20.
Dose-Response Pattern
We tested each signal for presence of a dose-response relationship. We first restricted the data to ever-users of the drug of interest and then estimated the incremental OR per prescription among the remaining users, while capping exposure at 50 prescriptions. This incremental OR corresponds to the slope of the dose-response curve. To evaluate whether a dose-response relationship was present, we tested the null hypothesis that the slope of the dose-response curve was zero. We arbitrarily selected a cutoff of p b 0.10.
Results
Following exclusions, the final study population consisted of 278,485 incident cancer cases. The most frequent cancers were ductal adenocarcinoma of the breast among females (n = 36,805), prostate adenocarcinoma among men (n = 34,443), and colon adenocarcinoma in both genders (n = 24,557). In the initial screening process, 22,125 drug-cancer pairs underwent evaluation. For the majority of cancer types (61 of 99), more than 100 drug-cancer pairs underwent evaluation.
A total of 4561 signals (i.e., drug-cancer pairs meeting criteria for strength of association) were identified in the initial screening process, most frequently for cancers of the lung (196 signals for squamous cell carcinoma, 178 for small cell carcinoma and 176 for other adenocarcinomas). For five of the 99 cancer types, we found no signals in the initial screening process (Table 1) .
Of the signals identified in the initial screening stage, 3464 (75.9%) failed to meet the criteria for dose-response relationship, 12 (0.2%) failed the test for outcome specificity, while 65 (1.4%) failed both criteria; thus leaving 1020 signals. The signals most commonly disqualified because of the specificity criterion were drug-cancer pairs involving squamous cell carcinoma of the pharynx and various types of lung cancer. An overview of the total number of cases, drug-cancer pairs undergoing evaluation, and final signals are displayed in Table 1 .
Of the final 1020 signals, 159 were observed among drug classes at the second level of the ATC-system, 351 among drug classes at the fourth level, and 510 for single agents (fifth level). Table 2 displays all signals indicating a reduced cancer risk associated with long-term use of a drug class (at second ATC level), among associations based on more than 100 exposed cases or 1000 exposed controls. Table 3 displays signals suggesting an increased risk with a similar restriction. The full list of all 1020 signals for drug classes at the second or fourth level of the ATC-system and for single drug substances are provided in Supplementary Results I-II, III-IV, and V-VI, respectively.
Discussion
In this large-scale nationwide screening study, we evaluated 22,125 drug-cancer pairs and identified 1020 signals (i.e., drug-cancer associations) that met the criteria for strength of association, specificity, and dose-response pattern. The majority of the identified signals (703 signals) indicated an increased cancer risk associated with the specific prescription drugs, while a smaller proportion (317 signals) were inverse associations indicative of a potential chemopreventive effect. Our findings constitute a broad basis for future comprehensive studies of signals suggesting a potential causal relationship between the specific drugs and cancer types. The public health importance of identifying carcinogenic effects of drugs is evident, since even small carcinogenic effects of widely used drugs will translate into numerous drug-induced cancer cases. Moreover, neutral associations have important value by reassuring prescribers and patients of the safety of drugs, which will promote their appropriate use. Lastly, identification of potential chemopreventive drug effects may provide a clue to development of new compounds for cancer prophylaxis and treatment.
The primary strength of our study is the use of the Danish nationwide health registries, ensuring a prescription history of up to 17 years and virtually complete ascertainment of cancer cases. The large study population also allowed evaluation of drug exposure in relation to risk of more rare cancers. The quality of the data in the Danish Prescription Registry (Kildemoes et al., 2011) and the Danish Cancer Registry (Gjerstorff, 2011) has been found to be high (Kildemoes et al., 2011; Gjerstorff, 2011; Statens Serum Institute and Danish Cancer Society, n.d.) . Lastly, the detailed stratification according to cancer histology avoided lumping of cancer types with markedly different histology. For example, lung cancer consists of squamous cell carcinoma, adenocarcinoma, small cell carcinoma, large cell carcinoma and carcinoids, among others. As these cancer subtypes have markedly different biology, it is unlikely that their development would be similarly affected by the same drugs.
The principal weakness of the study is the lack of adjustment for potential confounding from life-style factors. Although we adjusted for education and a measure of comorbidity, our analyses would benefit from adjustment for life-style factors, such as obesity, alcohol Under the null hypotheses and with the traditional α of 0.05, evaluation of 22,000 associations is expected to result in approximately 1100 false positive associations. Importantly, this pertains to the initial signals (n = 4561) before dose-response and specificity requirements. One way to handle this would be to adjust for multiple testing, e.g. Bonferroni correction (Rice et al., 2008) . Although such adjustment reduces the number of false positive associations, it also reduces the likelihood that a true association will be captured. Given the explorative nature of our screening study, we should not reject signals before they can be subjected to rigorous evaluation. Thus, we did not include any correction for multiple testing, as also recommended by others (Rothman, 1990) .
Some of the identified signals can be attributed to confounding by indication. This is most notable for the observed associations with lung cancers. As an example, drugs used to treat obstructive lung diseases exhibited a strong association with squamous cell carcinoma of the lung (OR, 2.61), which is likely explained by these drugs being used for chronic obstructive pulmonary disease (COPD), which is caused primarily by smoking (Supplementary Results I) . Nevertheless, our algorithm succeeded in identifying established or previously reported associations, such as the association between use of female hormone therapy and risk of ductal and lobular adenocarcinomas (International Agency for Research on Cancer, 2007) (OR 1.92 and 2.65, respectively, Supplementary Results V), and the association between the antihypertensive drug hydrochlorothiazide and lip cancer (Friedman et al., 2012) (OR 6.93, Supplementary Results V) . Such findings provide assurance that our approach is capable of identifying true associations. Some of the signals we have identified clearly warrant further investigation. For example, the two antibiotics pivmecillinam and sulfamethizole displayed odds ratios of about 13 and 6, respectively, for squamous cell carcinoma of the bladder (Supplementary Results V) . Both drugs are used specifically to treat urinary tract infections and, as such, this signal might reflect a carcinogenic effect of inflammation due to recurrent infections. However, as both drugs are designed to accumulate in the bladder lumen and because the signal was very strong, this signal should be considered a candidate for future studies. Such studies should be designed specifically for the individual drug-cancer association, by employing focused and comprehensive confounder adjustment and by focusing on etiologically relevant exposure windows for the specific cancer outcomes under study. When deciding whether a given drug-cancer association is worthy of further study, i.e., prioritizing the many signals reported in this study, parameters other than the strength of the association should be considered. Thought should be given to the potential for confounding by indication or contraindication as discussed above, as well as biological plausibility, e.g., by considering the pharmacological mechanism of the drug and/or drawing upon findings in other studies, whether experimental, clinical or observational. In addition, the potential public health impact of a putative association should be considered, as reflected by the number of attributable cases, the aggressiveness of the cancer outcome and the age of those affected. Finally, several drugs evaluated by the International Agency for Research on Cancer (IARC) have been categorized as probably (Group 2 A) or possibly (Group 2B) carcinogenic to humans, because epidemiological evidence has not been definitive, or because carcinogenicity has been demonstrated only in experimental animals (International Agency for Research on Cancer, 2012; Friis et al., 2015) . Additional studies and continued monitoring of the potential carcinogenicity of these drugs are of paramount importance.
Another valuable next step would be a full-scale replication of our study, a common approach in, e.g., genome-wide screening studies (NCI-NHGRI Working Group on Replication in Association Studies et al., 2007) . This would require access to data sources comparable to the Danish registries, and should ideally hold data on potential lifestyle confounders or health-seeking behaviour. The combined results of the index and replication studies would help prioritize the signals that warrant further research.
In conclusion, we have presented an approach for nationwide screening of associations between the use of prescribed medications and cancer risk. The results of this screening should undergo external validation and the single drug-cancer associations should be subject to tailored analysis, in order to enhance our understanding of carcinogenic or chemopreventive effects of prescription drugs.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.ebiom.2016.03.018.
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